What are the recommended paclitaxel dosing regimens for various cancer types and disease stages?

Paclitaxel Dosing by Cancer Type and Stage

For ovarian cancer stages II-IV, the standard regimen is paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5-6 every 3 weeks for 6 cycles, with dose-dense paclitaxel 80 mg/m² on days 1,8, and 15 plus carboplatin AUC 5-6 on day 1 every 3 weeks as an equally effective alternative. 1

Ovarian Cancer (Epithelial, Fallopian Tube, Primary Peritoneal)

Stage IA-IB, Grade 1

• Observation only (no chemotherapy needed; survival >90% with surgery alone) 2

Stage IA-IB, Grade 2

• 3-6 cycles of chemotherapy if comprehensive surgical staging performed 2

Stages II-IV (Advanced Disease)

Standard IV Regimens (Category 1):

• Paclitaxel 175 mg/m² IV over 3 hours + carboplatin AUC 5-6 on day 1, every 3 weeks × 6 cycles 1

• Dose-dense paclitaxel 80 mg/m² IV over 1 hour on days 1,8,15 + carboplatin AUC 5-6 on day 1, every 3 weeks × 6 cycles 1

• Weekly paclitaxel 60 mg/m² IV over 1 hour + carboplatin AUC 2 over 30 minutes, weekly × 18 weeks 1

• Docetaxel 60-75 mg/m² + carboplatin AUC 5-6 on day 1, every 3 weeks × 6 cycles (preferred for patients at high risk for neuropathy, e.g., diabetics) 2

Intraperitoneal Regimen for Stage III Optimally Debulked (<1 cm residual) (Category 1):

• Paclitaxel 135 mg/m² IV continuous infusion over 24 hours on day 1
• Cisplatin 75-100 mg/m² IP on day 2
• Paclitaxel 60 mg/m² IP on day 8 (max BSA 2.0 m²)
• Repeat every 3 weeks × 6 cycles 3, 1

This IP regimen increased survival by 16 months compared to standard IV therapy (65.6 vs 49.7 months) in the GOG 172 trial 2. However, only 42% initially completed all 6 cycles due to toxicity (leukopenia, infection, fatigue, renal toxicity, neurotoxicity), though completion rates have improved with experience 2. Use lower cisplatin dose of 75 mg/m² to reduce toxicity 2.

Previously Treated Ovarian Cancer (Recurrent)

• Paclitaxel 135 mg/m² or 175 mg/m² IV over 3 hours every 3 weeks 4

---

Breast Cancer

Adjuvant Treatment (Node-Positive)

• Paclitaxel 175 mg/m² IV over 3 hours every 3 weeks × 4 cycles, administered sequentially after doxorubicin-containing chemotherapy (e.g., 4 cycles of AC) 4

Metastatic or Relapsed Disease

• Paclitaxel 175 mg/m² IV over 3 hours every 3 weeks (after failure of initial chemotherapy or relapse within 6 months of adjuvant therapy) 4

Triple-Negative Breast Cancer (Stage II-III, Neoadjuvant)

• Pembrolizumab + carboplatin + paclitaxel, followed by pembrolizumab + cyclophosphamide + doxorubicin/epirubicin, then adjuvant pembrolizumab (Category 1) 5
• Alternative: Docetaxel/carboplatin/pembrolizumab (preoperative only) 5

Dose-Dense Regimens (Adjuvant)

• AC followed by weekly paclitaxel every 2 weeks 5
• TC (docetaxel/cyclophosphamide) 5

---

Non-Small Cell Lung Cancer (NSCLC)

Advanced Disease

• Paclitaxel 135 mg/m² IV over 24 hours followed by cisplatin 75 mg/m² on day 1, every 3 weeks 4

Neoadjuvant (Resectable Stage IIA-IIIB, No EGFR/ALK Alterations)

• Nivolumab 360 mg + platinum-doublet chemotherapy every 3 weeks × 4 cycles (Category 1):

  • Carboplatin AUC 5-6 + paclitaxel 175-200 mg/m² (any histology)
  • Cisplatin 75 mg/m² + paclitaxel 175-200 mg/m² (any histology)
  • Cisplatin 75 mg/m² + gemcitabine 1000-1250 mg/m² days 1,8 (squamous) 6

• Pembrolizumab 200 mg + cisplatin-based doublet every 3 weeks × 4 cycles (Category 1) 6

• Durvalumab 1500 mg + platinum-doublet every 3 weeks × 4 cycles (Category 1) 6

---

AIDS-Related Kaposi's Sarcoma

Two recommended schedules:

• Paclitaxel 135 mg/m² IV over 3 hours every 3 weeks (dose intensity 45 mg/m²/week) 4

• Paclitaxel 100 mg/m² IV over 3 hours every 2 weeks (dose intensity 50 mg/m²/week) - preferred for patients with low performance status as it is less toxic 4

Special modifications for HIV patients:

• Reduce dexamethasone premedication to 10 mg PO (instead of 20 mg)
• Initiate treatment only if neutrophil count ≥1,000 cells/mm³
• Reduce dose by 20% for severe neutropenia (<500 cells/mm³ for ≥1 week)
• Use G-CSF as indicated 4

---

Gastric Cancer (Second-Line)

Metastatic/Recurrent After Fluoropyrimidine-Based First-Line

• Paclitaxel injection 175 mg/m² IV on day 1, every 21 days 7
• Paclitaxel oral solution 200 mg/m² twice daily on days 1,8,15 of 28-day cycle (showed superior OS: 9.13 vs 6.54 months) 7

Gastric Cancer with Peritoneal Carcinomatosis

• Intraperitoneal paclitaxel 100 mg/m² weekly × 3 weeks, 1-week break, then 3 additional treatments 8

---

Occult Primary Adenocarcinoma

• Paclitaxel 200 mg/m² IV over 3 hours on day 1 + carboplatin AUC 6, every 3 weeks 9
• Alternative: Paclitaxel 200 mg/m² over 1 hour + carboplatin AUC 6 + etoposide 50-100 mg/day PO days 1-10, every 3 weeks 9

---

Key Toxicity Considerations

Dose-limiting toxicities vary by regimen:

• Standard IV paclitaxel/carboplatin: sensory peripheral neuropathy 2
• Dose-dense paclitaxel: increased anemia 2
• Docetaxel/carboplatin: increased neutropenia 2
• IP paclitaxel/cisplatin: leukopenia, infection, fatigue, renal toxicity, neurotoxicity 2

Treatment modifications:

• Do not repeat cycles until neutrophils ≥1,500 cells/mm³ and platelets ≥100,000 cells/mm³ (solid tumors) 4
• Reduce dose by 20% for severe neutropenia (<500 cells/mm³ for ≥1 week) or severe peripheral neuropathy 4

Hepatic impairment dosing (3-hour infusion):

• Transaminases <10× ULN and bilirubin ≤1.25× ULN: 175 mg/m²
• Transaminases <10× ULN and bilirubin 1.26-2.0× ULN: 135 mg/m²
• Transaminases <10× ULN and bilirubin 2.01-5.0× ULN: 90 mg/m²
• Transaminases ≥10× ULN or bilirubin >5.0× ULN: not recommended 4

Mandatory premedication (all patients): Dexamethasone 20 mg PO 12 and 6 hours before, diphenhydramine 50 mg IV 30-60 minutes before, and H2-blocker 30-60 minutes before paclitaxel 4